Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients

BACKGROUND: Trastuzumab has changed the prognosis of HER2+ breast cancer. We aimed to investigate the prognosis of ER+/HER2+ patients treated with trastuzumab, thus to guide escalation endocrine treatment in ER+ breast cancer. METHODS: ER-positive early breast cancer patients operated at Ruijin Hosp...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Li, Shuai, Wu, Jiayi, Huang, Ou, He, Jianrong, Zhu, Li, Chen, Weiguo, Li, Yafen, Chen, Xiaosong, Shen, Kunwei
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2021
Sujets:
Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8278709/
https://ncbi.nlm.nih.gov/pubmed/34256710
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-08555-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires